Osimertinib (Tagrisso, AstraZeneca) is indicated for 'the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy'.
The dosage schedule is available in the summary of product characteristics for osimertinib.
The list price of osimertinib (40 mg or 80 mg) is £5,770 per 30‑tablet pack (excluding VAT; BNF online accessed April 2026).
The company has a commercial arrangement (commercial access agreement). This makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, AstraZeneca's Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.